Literature DB >> 24904105

ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.

Eric Padron1, Sean Yoder2, Sateesh Kunigal3, Tania Mesa2, Jamie K Teer4, Najla Al Ali5, Mikkael A Sekeres6, Jeffrey S Painter3, Ling Zhang7, Jeffrey Lancet5, Jaroslaw P Maciejewski6, Pearlie K Epling-Burnette8, Eduardo Sotomayor1, Rami S Komrokji5, Alan F List5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24904105      PMCID： PMC4047502          DOI： 10.1182/blood-2014-03-562637

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease.

Authors:  Sa A Wang; Naomi Galili; Jan Cerny; Eric Sechman; Su Sin Chen; Jerome Loew; Qin Liu; Oluwole Fadare; Robert Hasserjian; Dan Jones; Huma Qawi; Bruce Woda; Azra Raza
Journal:  Am J Clin Pathol       Date:  2006-11       Impact factor: 2.493

2.  Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

3.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

4.  Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.

Authors:  Masashi Sanada; Takahiro Suzuki; Lee-Yung Shih; Makoto Otsu; Motohiro Kato; Satoshi Yamazaki; Azusa Tamura; Hiroaki Honda; Mamiko Sakata-Yanagimoto; Keiki Kumano; Hideaki Oda; Tetsuya Yamagata; Junko Takita; Noriko Gotoh; Kumi Nakazaki; Norihiko Kawamata; Masafumi Onodera; Masaharu Nobuyoshi; Yasuhide Hayashi; Hiroshi Harada; Mineo Kurokawa; Shigeru Chiba; Hiraku Mori; Keiya Ozawa; Mitsuhiro Omine; Hisamaru Hirai; Hiromitsu Nakauchi; H Phillip Koeffler; Seishi Ogawa
Journal:  Nature       Date:  2009-07-20       Impact factor: 49.962

5.  Clonal architecture of chronic myelomonocytic leukemias.

Authors:  Raphaël Itzykson; Olivier Kosmider; Aline Renneville; Margot Morabito; Claude Preudhomme; Céline Berthon; Lionel Adès; Pierre Fenaux; Uwe Platzbecker; Olivier Gagey; Philippe Rameau; Guillaume Meurice; Cédric Oréar; François Delhommeau; Olivier A Bernard; Michaela Fontenay; William Vainchenker; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

6.  AML1 mutations induced MDS and MDS/AML in a mouse BMT model.

Authors:  Naoko Watanabe-Okochi; Jiro Kitaura; Ryoichi Ono; Hironori Harada; Yuka Harada; Yukiko Komeno; Hideaki Nakajima; Tetsuya Nosaka; Toshiya Inaba; Toshio Kitamura
Journal:  Blood       Date:  2008-01-11       Impact factor: 22.113

7.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

8.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528
  8 in total
  9 in total

1.  Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.

Authors:  Ana Valencia-Martinez; Alessandro Sanna; Erico Masala; Elisa Contini; Alice Brogi; Antonella Gozzini; Valeria Santini
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

2.  Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.

Authors:  Michael Y Zhang; Jane E Churpek; Siobán B Keel; Tom Walsh; Ming K Lee; Keith R Loeb; Suleyman Gulsuner; Colin C Pritchard; Marilyn Sanchez-Bonilla; Jeffrey J Delrow; Ryan S Basom; Melissa Forouhar; Boglarka Gyurkocza; Bradford S Schwartz; Barbara Neistadt; Rafael Marquez; Christopher J Mariani; Scott A Coats; Inga Hofmann; R Coleman Lindsley; David A Williams; Janis L Abkowitz; Marshall S Horwitz; Mary-Claire King; Lucy A Godley; Akiko Shimamura
Journal:  Nat Genet       Date:  2015-01-12       Impact factor: 38.330

3.  A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Authors:  Eric Padron; Amy Dezern; Marcio Andrade-Campos; Kris Vaddi; Peggy Scherle; Qing Zhang; Yan Ma; Maria E Balasis; Sara Tinsley; Hanadi Ramadan; Cassandra Zimmerman; David P Steensma; Gail J Roboz; Jeffrey E Lancet; Alan F List; Mikkael A Sekeres; Rami S Komrokji
Journal:  Clin Cancer Res       Date:  2016-02-08       Impact factor: 12.531

Review 4.  Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.

Authors:  Anthony Hunter; Eric Padron
Journal:  Curr Hematol Malig Rep       Date:  2021-03-03       Impact factor: 3.952

Review 5.  CMML: Clinical and molecular aspects.

Authors:  Raphael Itzykson; Matthieu Duchmann; Nolwenn Lucas; Eric Solary
Journal:  Int J Hematol       Date:  2017-04-28       Impact factor: 2.490

6.  Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity.

Authors:  Meghan C Ferrall-Fairbanks; Markus Ball; Eric Padron; Philipp M Altrock
Journal:  JCO Clin Cancer Inform       Date:  2019-04

7.  Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.

Authors:  Giacomo Coltro; Abhishek A Mangaonkar; Terra L Lasho; Christy M Finke; Prateek Pophali; Ryan Carr; Naseema Gangat; Moritz Binder; Animesh Pardanani; Martin Fernandez-Zapico; Keith D Robertson; Alberto Bosi; Nathalie Droin; Alessandro M Vannucchi; Ayalew Tefferi; Anthony Hunter; Eric Padron; Eric Solary; Mrinal M Patnaik
Journal:  Leukemia       Date:  2019-12-13       Impact factor: 11.528

8.  An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Authors:  E Padron; G Garcia-Manero; M M Patnaik; R Itzykson; T Lasho; A Nazha; R K Rampal; M E Sanchez; E Jabbour; N H Al Ali; Z Thompson; S Colla; P Fenaux; H M Kantarjian; S Killick; M A Sekeres; A F List; F Onida; R S Komrokji; A Tefferi; E Solary
Journal:  Blood Cancer J       Date:  2015-07-31       Impact factor: 11.037

9.  Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup.

Authors:  Elena Ciabatti; Angelo Valetto; Veronica Bertini; Maria Immacolata Ferreri; Alice Guazzelli; Susanna Grassi; Francesca Guerrini; Iacopo Petrini; Maria Rita Metelli; Maria Adelaide Caligo; Simona Rossi; Sara Galimberti
Journal:  Oncotarget       Date:  2017-03-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.